Biosimilars Wedge Issue: Actavis Splits With GPhA In Supporting Calif. Notification Bill
Executive Summary
PhRMA, BIO and Abbvie also back California bill that would require pharmacists to notify physicians of biosimilar substitution while GPhA, Boehringer Ingelheim and Novartis oppose it.